Navigation Links
Tarsa Therapeutics Presents Positive Efficacy and Safety Data Comparing Its Oral Calcitonin to Nasal Calcitonin and Placebo in Phase III Osteoporosis Treatment Trial
Date:9/19/2011

for osteoporosis patients and their physicians."

According to the International Osteoporosis Foundation, studies indicate that up to half of osteoporosis patients stop their treatment after just one year.  In one study, two-thirds of osteoporosis patients said their medication interfered with their lives in some way and over 20% of the women who missed or stopped their treatment said it was due to side effects.

"The encouraging efficacy and safety data presented at the ASBMR meeting, including data showing that OSTORA demonstrated superior efficacy to nasal calcitonin, reinforces our view that OSTORA has the potential to address an unmet need in current therapy," noted David Krause, MD, Chief Medical Officer of Tarsa.  "Data suggest that approximately two million women in the U.S. alone have discontinued osteoporosis treatment for various reasons, which include poor tolerance or the perceived risk of adverse effects, leaving them more vulnerable to potentially disabling fractures.  Reports from the field suggest many other newly diagnosed osteoporosis patients have not started drug treatment as a result of safety concerns.  The data presented today indicate that once-daily OSTORA may have the potential to provide an effective, safe and convenient new option for these millions of women and their physicians."

Calcitonin is approved for the treatment of postmenopausal osteoporosis, but its use has been limited by the fact that it is currently available only in intranasal and injectable forms.  Prior clinical studies show that Tarsa's oral calcitonin tablet delivers calcitonin effectively and reduces blood levels of bone resorption biomarkers.

"We view the new OSTORA data presented today as very promising news for osteoporosis patients and their physicians seeking additional treatment options," said David Brand, President and CEO of Tarsa.  "We look forward to filing a New Drug Application for OSTORA with the F
'/>"/>

SOURCE Tarsa Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tarsa Therapeutics Reports Positive Top-Line Results From Pivotal Phase III ORACAL Trial of its Oral Calcitonin in Treatment of Postmenopausal Osteoporosis
2. Tarsa Therapeutics Completes Phase III Trial of its Oral Calcitonin for Treatment of Postmenopausal Osteoporosis and Initiates Phase II Trial in Osteoporosis Prevention
3. Silence Therapeutics Announces Issuance of Japanese Patent for Screening Therapeutics Against Key Pathway Associated with Cancer and Other Diseases
4. Echo Therapeutics Receives Registered Trademarks for Symphony® and Prelude®
5. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the UBS 2011 Global Life Sciences Conference in New York City
6. ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20)
7. Rare Disease Therapeutics, Inc. Selects Accredo Health Group to Distribute Anascorp® for the Treatment of Centruroides Scorpion Sting Envenomation
8. Silence Therapeutics and InteRNA Technologies Sign Collaboration to Develop Novel microRNA Therapeutics
9. Nile Therapeutics to Present at Rodman & Renshaw Global Investment Conference
10. Regulus Therapeutics to Present New Advancements in microRNA Therapeutics for Treatment of Metabolic Diseases and Cancer
11. Global Sepsis Therapeutics Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Calif. , Aug. 31, 2015  Regulatory ... and government, where regulations are often strict and ... is driving a demand for professionals who have ... these regulations across a product lifecycle and demonstrate ... The University of California, Irvine Extension , ...
(Date:8/31/2015)... , Aug. 31, 2015 Regen BioPharma, ... development of a novel means of delivering its ... RGBP-248, to liver tumors utilizing a clinically approved ... overcomes previous hurdles with gene silencing therapeutics in ... delivered throughout the whole body.  By utilizing a ...
(Date:8/31/2015)... MOUNTAIN VIEW, Calif. , Aug. 31, ... EURONEXT: SAN) and the life sciences team at Google ... and outcomes for people with type 1 and type ... and devices with Google,s expertise in analytics, miniaturized electronics ... how to improve diabetes care by developing new tools ...
Breaking Medicine Technology:UC Irvine Extension Launches New Regulatory Affairs and Compliance Certificate Program 2UC Irvine Extension Launches New Regulatory Affairs and Compliance Certificate Program 3Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 3Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 2Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 3Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 4Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 5Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 6
(Date:8/31/2015)... ... August 31, 2015 , ... The 2015 New York ... and family members, medical professionals, and researchers, covering a variety of topics related ... a collaborative effort between the Mesothelioma Applied Research Foundation and Memorial ...
(Date:8/31/2015)... ... ... The Bay Pines VA Healthcare System (VAHCS) remains focused on ... doctors and nurses and expanding existing facilities and services. Spine surgery will soon ... Jabre was selected to lead and grow the Bay Pines VAHCS’s new spine surgery ...
(Date:8/31/2015)... , ... August 31, 2015 , ... ... Surgery Program at Monmouth, was one of the first doctors in the area ... of this new approach have been impressive: faster recovery, decreased immediate and long-term ...
(Date:8/31/2015)... , ... August 31, 2015 , ... Dr. Stewart ... may be prevented during Amblyopia Awareness Month. Only a comprehensive eye examination can diagnose ... common cause of visual impairment among children, affecting approximately 2 to 3 out of ...
(Date:8/31/2015)... ... August 31, 2015 , ... The dental implant and prosthetic market in the ... Implant Dentistry. (See Press Room ) More than 30 million Americans are missing ... the increasing demand for dental implants, the National Association of Dental Laboratories (NADL) created ...
Breaking Medicine News(10 mins):Health News:New York Experts on Mesothelioma Come Together at Memorial Sloan Kettering Cancer Center 2Health News:New York Experts on Mesothelioma Come Together at Memorial Sloan Kettering Cancer Center 3Health News:Neurosurgeon Selected to Lead Growing Spine Care Program 2Health News:Neurosurgeon Selected to Lead Growing Spine Care Program 3Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 2Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 3Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 4Health News:Renowned Eye Surgeon Dr. Stewart Shofner Shares Information about the Causes of Lazy Eye During Amblyopia Awareness Month 2Health News:Renowned Eye Surgeon Dr. Stewart Shofner Shares Information about the Causes of Lazy Eye During Amblyopia Awareness Month 3Health News:Dental Association Raises Awareness as Implant Industry Grows 2Health News:Dental Association Raises Awareness as Implant Industry Grows 3Health News:Dental Association Raises Awareness as Implant Industry Grows 4
... Taiwan researchers said Thursday they have successfully tested 10 ... while prolonging patients' survival time with limited side ... led by Dr. Wong Chi-huey, president of Taiwan's highest ... in the structure and function of sugars. ...
... all financial aid to Amnesty International and called on ... accusing it of promoting abortion. "No more Catholic ... said a statement from the Vatican's Pontifical Council for ... Renato Martino, said the "suspension of all financing of ...
... concept catching up fast in the West. ,With the ... phones with hundreds of names and numbers stored in its ... these numbers belong to the near and dear. ,In ... had a heart attack and the physicians attending on the injured ...
... for Allergy & Immunology (LIAI) made an important finding, ... for treating autoimmune and inflammatory diseases such as ... studies, conducted in laboratory mice, demonstrated the role of ... broken down in the body, in regulating inflammation. ...
... Melbourne's Yarra River, posing serious threat to wildlife in the ... with the water until the slick - from the Chandler ... ,The Environment Protection Agency (EPA) is investigating the source ... but was not discovered until Tuesday by a kayaker using ...
... University of Illinois at Chicago and Cornell University are ... patients who suffer from Neurodegenerative diseases or stroke . ... events take place that lead to the death of ... called histone deacetylases can modulate gene expression, and in ...
Cached Medicine News:Health News:Taiwan Researchers Claim Cancer Therapy Alternative 2Health News:Catholics Should Halt Amnesty Support Over Abortion Issue: Vatican 2Health News:Look Out for ICE in Emergency Situations 2Health News:New Therapeutic Approach for Autoimmune and Inflammatory Diseases 2Health News:Australia Battles Oil Slick on Yarra River 2Health News:Researchers Developing New Therapy to Re-activate Silenced Genes 2
LUMIGAN® is a powerful eye drop medication for lowering IOP. IOP is short for intraocular pressure or eye pressure. LUMIGAN® is the first in a new class of medication....
... New REFRESH LIQUIGEL® Lubricant Eye Drops ... with the convenience of a liquid ... protection. Its extra-strength CMC formula provides ... comfort. And with the PURITE® preservative, ...
Due to its thick formula, REFRESH CELLUVISC Lubricant Eye Drops is ideal for persistent dry eye conditions. REFRESH CELLUVISC provides lasting relief and protection for dry, scratchy eyes....
... solution is an anti-infective prescription ... may instruct you to use ... infection caused by bacteria. Bacterial ... the 2 types of eye ...
Medicine Products: